![Figure 2.](/tables/wjon843w-g002.jpg)
Figure 2. Patient developed response after pazopanib (800 mg/day) with resolution of brain metastasis. (A) Coronal T1-weighted scan with gadolinium contrast demonstrating small sub-centimeter contrast enhancing lesions (yellow arrow) on baseline MRI scan (left panel) that resolved after 3 months of pazopanib (right panel). (B) Axial T1-weighted baseline MRI scan with gadolinium showing small sub-centimeter metastasis (left panel) that resolved after 3 months of pazopanib (right panel).
![Figure 3.](/tables/wjon843w-g003.jpg)
Figure 3. Patient developed response after re-challenge schedule of reduced-dose pazopanib (600 mg/day) with reduction in size of left parietal brain metastasis. (A) Coronal T1-weighted scan with gadolinium contrast demonstrating contrast enhancing lesions (yellow arrow) on baseline MRI scan (left panel) in left parietal region that resolved after 3 months of pazopanib (right panel). (B) Axial T1-weighted baseline MRI scan with gadolinium showing left parietal metastasis (left panel) that resolved after 3 months of pazopanib (right panel).